SIU School of Medicine

Jump directly to a section:

A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 sq cm to less than or equal to 36 sq cm

IRB Number

12-638 Identifier


Trial Status

Open for Enrollment
Phase 3

Why is this study being done?

To demonstrate the efficacy and safety of the investigational topical treatment known as HP802-247 to promote the healing of venous leg ulcers

Who is eligible to participate?

Patients with venous leg ulcers greater than 12 sq sm and less than or equal to 36 sq cm in area.

What is involved?

Patients will have three run-in study visits during which healing rate of their ulcers and their general health will be evaluated. If they are eligible for enrollment, they will have 12 weekly visits for study drug or placebo treatment, then they will have six follow-up visits after study treatment until they have completed 12 months of study participation.

How long is the study?

12 months

Who can I contact for additional information?

Tiffany Whitaker, RN (217) 545-2531

Who is the Principal Investigator of this study?

Doug Hood, MD

Where is the trial located?

Springfield, Illinois